Business Wire

Veezi Signs Deal with CanalOlympia, Vivendi's Pan African Cinema Network

Del

Vista Group International (NZX & ASX: VGL) company Vista Entertainment Solutions (‘Vista Cinema’) and Vivendi’s CanalOlympia have signed an agreement to roll-out Vista Cinema’s Veezi across all their cinema venues. Veezi, already utilised by cinemas in 27 countries, is Vista Cinema’s SaaS cinema management solution for Independent cinemas.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180924006098/en/

Currently operating 9 venues across 7 countries, CanalOlympia is the leading network of cinema and live performance venues in Africa. Several additional sites are set to open in the months to come, extending the breadth of the CanalOlympia footprint. The CanalOlympia operation showcases the diversity of African culture and has helped bring cinemas back to countries currently short on entertainment choices and cultural infrastructure.

The venues include the latest projection and sound technologies. They produce their own electricity via installed solar panels – an example of the CanalOlympia approach to growing its offer in sometimes challenging areas. To help them manage their circuit venues spanning different markets, CanalOlympia required a management solution that their local staff could easily use but one that would also leverage the synergies of their sites operations and enable central reporting.

“The decision to choose Veezi was made to take advantage of a system that focuses on cinema ticketing,” said Barbara Weill Head of Programming and Communication, CanalOlympia. “Using Veezi will allow CanalOlympia to manage the sites homogenously and save a lot of time every week. The solution is a great choice for our operations and we’re very excited about it. The fact that Veezi is engineered by and supported by Vista Cinema – the most experienced cinema management software provider – is an additional bonus.”

“The CanalOlympia operation is a fantastic project for Veezi to be part of. Clients that push the innovation front as CanalOlympia clearly does, provide us with equal opportunity to innovate and push Veezi functionality to new heights. We’re delighted to further extend our part in supporting Africa’s cinema industry by partnering with this very special company,” said Mischa Kay, Managing Director, Vista Cinema, for EMEA.

CanalOlympia have also partnered with Orange to promote the Cineday two-for-one SMS voucher program and Orange Money, their mobile payment solution, both of which will benefit from a Veezi integration. Later this year, CanalOlympia will integrate Orange Money payments with Veezi’s internet ticketing solution, to allow customers to purchase tickets from the CanalOlympia website.

The CanalOlympia/Veezi roll-out will commence in October 2018 and conclude in February 2019 when the Circuit’s new sites are commissioned.

About Veezi, engineered by Vista:

Veezi is a cloud-based SaaS cinema management solution built specifically for cinema exhibitors in the Small Circuit Market, categorized as those with fewer than 20 screens, also referred to as ‘Independent’ Cinemas. Veezi has customers in more than 25 countries with the total market opportunity estimated to exceed 20,000 cinema sites. Like the Vista Cinema suite, new functionality is continuously added to Veezi to meet the growing demands of the Independent Cinema community and its moviegoers.

Website: www.veezi.com
Twitter: @VeeziByVista

Facebook: www.facebook.com/veezibyvista

About Vista Entertainment Solutions:

Vista Entertainment Solutions Ltd (‘Vista Cinema’) is the world leader in cinema management software solutions with installations in more than 90 countries around the world and an estimated 40% global market share in the Large Cinema Circuit market. The Vista Cinema software product line comprises multiple modules, integrated and scalable, suited to cinema exhibitors operating 20+ screens and 100s of cinemas. Vista Cinema is head-quartered in Auckland, New Zealand and has subsidiaries incorporated in Los Angeles, London, Shanghai, Beijing, Cape Town and Mexico City.

Website: www.vista.co
Twitter: @VistaCinema
LinkedIn: www.linkedin.com/company/vista-entertainment-solutions

About CanalOlympia:

CanalOlympia is the leading network of cinema and live performance venues in Africa. Several dozen venues are set to open in central and western African countries, where entertainment and cultural infrastructures are often lacking, appealing to a population with an increasing appetite for cultural content. Nine venues have been opened to date (June 2018) in Conakry (Guinea), Yaoundé and Douala (Cameroon), Niamey (Niger), Dakar (Senegal), Lomé (Togo), Cotonou (Benin) and two in Ouagadougou (Burkina Faso). The venues are structured around a modular movie theater with 300 seats, which can be transformed into an open-air stage with space for an audience of several thousands. The venues are fitted with the latest projection and sound technologies and use energy provided by solar panels. CanalOlympia is part of the Vivendi group.

Contact information

For Veezi
Emanuele De Plano, Vista Entertainment Solutions
+33 6 89 82 54 89
emanuele.deplano@vista.co
or
For CanalOlympia
Jean-Louis Erneux
+33 1 71 71 15 84
jean-louis.erneux@vivendi.com

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Incyte Announces Positive Interim Data from Phase 2 Trial of Pemigatinib, Its Selective FGFR Inhibitor, in Patients with Cholangiocarcinoma21.10.2018 10:45Pressemelding

Incyte Corporation (Nasdaq:INCY) announces updated data from its ongoing Phase 2 FIGHT-202 trial evaluating pemigatinib (INCB54828), its selective fibroblast growth factor receptor (FGFR) inhibitor, in patients with advanced/metastatic or surgically unresectable cholangiocarcinoma (bile duct cancer) who failed at least one previous treatment. In patients with FGFR2 translocations who were followed for at least eight months, interim study results demonstrated an overall response rate (ORR) of 40 percent, the primary endpoint, and a median progression free survival (PFS) of 9.2 months, a key secondary endpoint. These results are being presented at the European Society for Medical Oncology (ESMO) 2018 Congress in Munich, Germany in a poster presentation on Sunday, October 21 from 12:45 p.m. CEST to 1:45 p.m. CEST (6:45 a.m. ET to 7:45 a.m. ET). (Location: Hall A3 – Poster Area Networking Hub; Abstract #756P) “We are pleased to share updated interim results from our ongoing FIGHT-202 trial

Servier and Taiho Oncology Announce Phase III LONSURF® Study Has Met Primary and Secondary Endpoints Demonstrating Prolonged Overall Survival and Progression-Free Survival in Patients with Refractory Metastatic Gastric Cancer21.10.2018 09:10Pressemelding

Servier and Taiho Oncology, Inc. (U.S.), a subsidiary of Taiho Pharmaceutical Co., Ltd. (Japan), jointly announced today clinical data from the pivotal Phase III TAS-102 Gastric Study (TAGS) evaluating LONSURF® (trifluridine/tipiracil, TAS-102) versus placebo and best supportive care in patients with heavily pre-treated metastatic gastric cancer who have progressed or are intolerant to previous lines of therapy. The study met its primary endpoint of prolonged overall survival (OS) and secondary endpoint measures of progression-free survival (PFS) consistently supported the OS results, as well as continuing to demonstrate the predictable safety and tolerability profile of trifluridine/tipiracil. Data from TAGS was presented by Dr. Hendrik-Tobias Arkenau, Executive Medical Director of the Sarah Cannon Research Institute UK and an investigator for TAGS, at the ESMO 2018 Congress in Munich, Germany during an oral session (Abstract #LBA25). The study results were simultaneously published in

Phase 3 Data on Filgotinib in Biologic-Experienced Rheumatoid Arthritis to Be Presented at 2018 ACR/ARHP Annual Meeting20.10.2018 22:30Pressemelding

Gilead Sciences, Inc. (Nasdaq: GILD) and Galapagos NV (Euronext & NASDAQ: GLPG) today announced detailed results from the Phase 3 FINCH 2 clinical trial of filgotinib, an investigational, selective JAK1 inhibitor, in adults with moderately-to-severely active rheumatoid arthritis and prior inadequate response or intolerance to biologic agents. The data, which are being presented as a late-breaking poster at the 2018 American College of Rheumatology/Association of Rheumatology Health Professionals (ACR/ARHP) Annual Meeting in Chicago, suggest filgotinib has a potential role in addressing important unmet needs in the treatment of rheumatoid arthritis. Positive efficacy data from FINCH 2 were previously announced in September 2018. The data show statistically significant improvements in the proportion of patients achieving a range of clinical efficacy endpoints, including the proportion of patients achieving American College of Rheumatology 20 percent (ACR20, primary endpoint), 50 percent

Manchester United and True Religion Launch Denim Range19.10.2018 17:37Pressemelding

Manchester United (NYSE:MANU) and luxury denim brand True Religion have collaborated to launch a range of premium club branded denim wear. A first for the club, the new global partnership with the iconic American denim brand will see a range of men’s & women’s co-branded styles go on sale beginning 26th October in the club’s Megastore as well as online via United Direct and truereligion.com & eu.truereligion.com. The exclusive collection features jeans, shirts and jackets, including a highly desirable limited edition denim jacket embroidered with the club’s crest. Fans will have the opportunity to win a selection of clothing from the new range by visiting www.manutd.com/truereligion. Manchester United’s Group Managing Director, Richard Arnold, comments: “True Religion is a well-known, established name in fashion, creating unique designs without compromising on quality. The range we have collaborated on includes the same attention to detail and craftsmanship that has made True Religion

Arch Insurance Announces Strategic Leadership Changes19.10.2018 13:10Pressemelding

Arch Insurance today announced that Matt Shulman will assume the newly created role of CEO, Arch Insurance North America, effective January 1, 2019. In this role, he will lead Arch Insurance’s operations in the United States and Canada. He will report to Nicolas Papadopoulo, Chairman and CEO of Arch Worldwide Insurance Group. Mr. Shulman, who has more than 20 years of experience in the insurance industry, has been with Arch Insurance since 2009 and has served as the President and CEO of Arch Insurance Europe since 2016. “Matt brings significant U.S. and international experience to this role. Under his leadership, together with our senior team, Arch Insurance will continue to enhance our value proposition to our customers through a robust, diversified product portfolio, creative solutions and excellent service,” Mr. Papadopoulo said. Arch Insurance has also created a new organizational structure with three Chief Underwriting Officers (CUO) dedicated to specific lines of business. These

Takeda to Present Results from Phase 3 ALTA-1L Trial Highlighting Intracranial Efficacy of ALUNBRIG® (brigatinib) Versus Crizotinib in First-Line Advanced ALK+ Non-Small Cell Lung Cancer19.10.2018 12:00Pressemelding

Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that intracranial efficacy data from the Phase 3 ALTA-1L (ALK in Lung Cancer Trial of BrigAtinib in 1 st Line) trial showed improved intracranial progression-free survival (PFS) and intracranial objective response rate (ORR) with ALUNBRIG (brigatinib) compared to crizotinib among anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer (NSCLC) patients. Data for these secondary endpoints will be presented in a poster discussion at the European Society for Medical Oncology (ESMO) 2018 Congress on Friday, October 19 at 2:00 p.m. CET in Munich, Germany. These results further support ALUNBRIG as a potential treatment for adults with ALK+ locally advanced or metastatic NSCLC who had not received a prior ALK inhibitor. ALUNBRIG is currently not approved as first-line therapy for advanced ALK+ NSCLC. “ALK+ NSCLC often spreads to the brain, so having options that can clearly demonstrate efficacy both in the brain an